Prevnar™

BIOLOGICAL4 trials

Sponsors

GlaxoSmithKline, Merck Sharp & Dohme LLC

Conditions

Hepatitis AMalariaPneumococcal InfectionsTuberculosis

Phase 1

Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)

CompletedNCT01215175

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2009-09-25End: 2011-01-05Updated: 2019-03-18

Phase 2

Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine

CompletedNCT00323622

GlaxoSmithKlineMalaria

Start: 2005-04-30End: 2007-05-31Updated: 2016-12-09

Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants

CompletedNCT01098474

GlaxoSmithKlineTuberculosis

Start: 2010-07-07End: 2012-03-16Updated: 2019-06-27

Phase 3

Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age

CompletedNCT00197002

GlaxoSmithKlineHepatitis A

Start: 2003-09-11End: 2006-01-16Updated: 2018-08-06

Related Papers

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial.

2014-08-0942 citations

Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.

2009-08-0181 citations